The Food and Drug Administration has expanded the approval of Avycaz (ceftazidime and avibactam) to include pediatric patients aged ≥3 months for the treatment of complicated intra-abdominal infections, used in combination with metronidazole, and for complicated urinary tract infections.
Recommendations have been developed for use of polymyxins, focusing on polymyxin B and polymyxin E (colistin); the guidelines were recently published in Pharmacotherapy.
Delaying or withholding antibiotics for older patients with a urinary tract infection (UTI) is associated with an increase in bloodstream infection and all-cause mortality.
Algorithms that combine Internet of Things (IoT) technologies and in-home sensory devices with machine learning techniques can be used to monitor the health and well-being of people with dementia.
For this study, the authors identified randomized controlled trials (RCTs) that compared SGLT2 inhibitors with placebo, no treatment, or another antidiabetic agent and reported on UTI outcome.
Exposed patients with ESC-R EB UTIs were matched to unexposed patients with EB UTIs based on study year (151 in each group).
A total of 252 patients in the cefiderocol group and 119 patients in the imipenem-cilastatin group had a qualifying Gram-negative uropathogen and were included in the analysis of the primary end point of a composite of clinical and microbiological outcomes seven days after cessation of treatment.
There were 327 cystitis episodes overall, 111 and 216 in the water and control groups, respectively.
During the first 6 hours after receiving the drug, the patient voided 850mL, and pain remained controlled. On ultrasonography, bladder volume was 77mL one day later.
Adjusted rates of revisits leading to admission were similar between patients who received parenteral antibiotics and those who did not receive parenteral antibiotics (risk difference, 0.3%).
